Who we are
MirZyme is built by a team of committed and experienced individuals working at the forefront of medical research and business.
About MirZyme
MirZyme Therapeutics Limited is an active UK biotechnology company incorporated in Birmingham in 2016. Founded by vascular scientist Professor Asif Ahmed, the company is developing diagnostic and therapeutic programmes for preeclampsia, led by M-PREG® and MZe786.
The company is developing end-to-end solutions for problems in pregnancy. The founder and CEO is Professor Asif Ahmed, who also founded Aston Medical School. He is a world-renowned entrepreneurial scientist whose research has identified vascular-protective pathways implicated in preeclampsia.
MZe786 was awarded an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP), providing MirZyme with access to coordinated regulatory and development support as the programme progresses.
Management Team
Chairman and CEO
Asif Ahmed is the founder of MirZyme and a world-renowned British scientist who discovered two protective pathways that can be used to predict, prevent and treat preeclampsia.
Dr May Rezai
Chief Operations Officer
May Rezai obtained her PhD in 2021 and has been working with MirZyme from its inception. She is also the Chair of a UK-wide community based charity.
Mr Mike Vousden
Financial Director
Mike Vousden has been a chartered accountant for over 25 years. He is responsible for all the financial aspects of the company.
Dr Faraz Ahmed
Clinical Safety Officer
Faraz Ahmed is an NHS doctor in emergency medicine with prior experience in general and vascular surgery. He has a background in Biochemistry and is the clinical lead for MirZyme's diagnostic assets and their implementation.
.png)
.jpg)
Dr Pathik Brahmkshatriya
Preclinical Development Director
Pathik is a medicinal chemist with >20 years of experience in early stage drug discovery including NCE and 505(b)(2) pathways. Having worked extensively with global CROs for IND-enabling studies including an IND approval by U.S. FDA; he is responsible for complete IND developmental activities at Mirzyme.
Non Executive Directors
Dr Malcolm Barratt-Johnson
Non-Executive
Malcolm Barratt-Johnson is a Physician Scientist and the past president of the Royal Society of Medicine (Pharmaceutical Medicine). He is a lead medical assessor for MHRA and EMA. Malcolm is the MD of PharmaMedic Consultancy Limited.
Mr Sami Ahmad
Non-Executive
Sami Ahmad is CFO of Trecora Resources, a public NYSE-listed (TREC) leading
company in chemicals based in Houston, Texas. Sami has an MBA in finance from the University of Chicago.
Non-Executive
Julia Elizabeth King, Baroness Brown of Cambridge, DBE FREng FRS is a British
engineer and crossbench member of the House of Lords. She was a managing director at Rolls Royce and a member of the governing board of the European Institute of Innovation and Technology.
Dr Wenda Ramma
Non-Executive
Wenda Ramma has a Ph.D. in Vascular Biology and an Executive MBA from the UCLA. Wenda is the Medical Science Liason (Cardiovascular) at Bristol-Myers Squibb. At Amgen Wenda supported the launch of Repatha and other cardiovascular products.
Scientific Advisory Board
Prof Stephen Smith
Chairman
Professor Stephen K. Smith was the first to identify soluble Flt-1 in human placenta and is the former Dean of Medicine at Imperial College & CEO of Imperial College Healthcare.
Dr Swati Agrawal
Member
Dr Swati Agrawal is a maternal fetal medicine doctor in Toronto and has focused her research on preeclampsia.
Dr Allyah Abbas-Hanif
Member
Allyah Abbas-Hanif is an experienced pharmaceutical physician with more than a decade of proficiency in taking drugs from concept to global markets. She is trained in cardiology with an interest in maternal health.